TeleZenMD review 2026: the whole-system weight-loss play, examined

TeleZenMD is a cash-pay telehealth company operating in all 50 states, founded by Lina and Eric Viner — a married couple based in Florida who position the company explicitly against what they call the "prescription-and-a-portal" norm. The pitch, repeated across the site, is that medication alone doesn't change the habits that drive weight gain, so care should bundle three things: physician-guided treatment, a real concierge support team you can call or text, and a structured behavioral program included with every plan.

Where most of the providers we cover are essentially GLP-1 weight-loss funnels with a few adjacent products, TeleZenMD runs parallel programs across a much wider menu: standard and microdose GLP-1 weight loss, sermorelin for sleep and recovery, NAD+ and glutathione for energy and longevity, MIC/B12 metabolic injections, PT-141 for sexual health, methylene blue for "brain health," women's hormone therapy (estradiol and progesterone in several formats), women's hair-loss treatments (a GHK-Cu foam, an oral, a shampoo, a topical), and prescription skincare (tretinoin, hydroquinone, estriol, GHK-Cu, and an NAD+ face cream). That breadth is what distinguishes TeleZenMD from the GLP-1-focused funnels, and it's why it maps onto more of PeptideWellness's categories than any other provider in our set.

Medications are prescribed by licensed providers after an online intake and prepared by U.S. compounding pharmacies. The company says it offers both compounded and branded GLP-1 options "when medically appropriate and legally permissible," with the choice left to the prescribing provider — a hedge that reflects how fluid the regulatory picture is in 2026.

TeleZenMD publishes its full price ladders on the product pages, before any intake — a useful starting point, since this is a cash-pay category where the headline number isn't the whole picture. Below are the live ladders, pulled directly from the GLP-1 therapy and microdose pages on 10 June 2026.

Prices current as of 10 June 2026, taken from TeleZenMD's live product pages. This is a cash-pay market where rates and promotions move; we re-verify pricing periodically and update this page when it changes. The most regulation-sensitive line — compounded tirzepatide — we'll recheck after the FDA's 29 June 2026 comment deadline (see section 06).

Standard GLP-1 — compounded semaglutide

Standard GLP-1 + GIP — compounded tirzepatide

Microdose GLP-1 (lower-dose protocol)

A few things worth flagging plainly. The headline "as low as $133/month" is real, but it's the annual semaglutide plan, which means paying $1,598 in full at checkout. The monthly-equivalent framing is honest about being an equivalent — the company states multi-month plans are paid in full upfront — but a patient skimming the hero banner could miss that the low number requires a four-figure commitment on day one. Buy-now-pay-later options (Klarna, Affirm, Afterpay) soften the blow, and plans are FSA/HSA eligible, which is a genuine advantage other cash-pay competitors don't all offer.

The promo-code picture is messier than the pricing. We counted at least four overlapping intro offers across the site: a site-wide $100 off first order (WELCOME100), a microdose-specific $25 off (MICRO25), a $50 off (TELE50ZEN) on several non-GLP-1 programs, and a stray SAVE25 on the sermorelin page. Some are auto-applied; we could not confirm which stack. Treat the "first month" numbers above as before any code, and expect the real first-month figure to be lower depending on what applies.

The company states there are no hidden fees and no required memberships, and that you can pause or cancel from the patient portal as long as you do so before the next order is processed. Those are the company's stated terms, taken from the patient portal copy.

How that lands against the set. TeleZenMD's entry monthly rate ($198 for standard semaglutide, $148 for microdose) sits in the middle of the market — well above the budget tier's sticker prices but below the premium concierge clinics. The annual-plan equivalents ($133–$149/mo) are competitive, but only if you're willing and able to prepay. We've deliberately kept head-to-head price comparisons out of this review; you'll find those in our comparison pages.

The funnel is the standard U.S. cash-pay telehealth model — worth explaining for readers used to other systems, because there is no "leave your number and we'll call you" gate here.

Online intake. You start a secure questionnaire (separate intake flows exist for standard GLP-1, microdose, and each non-weight-loss program). It collects health history and goals. General eligibility for GLP-1 care is described as a BMI of 27 or higher with at least one weight-related health consideration, or other clinical indications — but the company is careful to say meeting the BMI threshold doesn't guarantee approval.

Provider review. A licensed physician reviews your information — the company says medical review typically happens within about 24 hours — and decides whether a plan is appropriate.

Pharmacy and shipping. If approved, the prescription is compounded by a U.S. partner pharmacy (about 48 hours) and shipped (about 2 business days), discreetly and for free. Total time to your door is quoted at roughly 5 business days.

Ongoing care. You get a patient portal, secure messaging with providers, the concierge support line (call or text), and access to the behavioral program and education materials.

The price you see on the product page is the price you carry into checkout; the intake exists to determine eligibility and take payment, not to unlock a hidden quote. That's the answer to the most common worry about these funnels: at TeleZenMD, the number is public first.

TeleZenMD's weight-loss results ride on the molecules, not the brand — so the honest question is what compounded semaglutide and tirzepatide can do, and what's realistic. The company cites the standard pivotal trials.

For semaglutide, the landmark STEP 1 trial found adults with overweight or obesity lost on average around 15% of body weight over 68 weeks on once-weekly 2.4 mg, versus roughly 2–3% on placebo, alongside lifestyle support. For tirzepatide, the dual GLP-1/GIP agonist, the SURMOUNT-1 trial and the head-to-head SURMOUNT-5 trial (NEJM, 2025, tirzepatide vs. semaglutide) showed larger average loss — into the ~20%+ range at higher doses over longer periods. TeleZenMD's own summary — "10 to 15 percent over approximately 6 months," "up to 15 to 22 percent over longer study periods" — broadly tracks that literature, though the "15% in roughly six months" end is on the optimistic side: in the STEP trial, the ~15% average was reached at 68 weeks, with six-month figures closer to 10%.

Two honest caveats we'd put on the page. The trials studied branded, FDA-approved semaglutide and tirzepatide at defined doses. TeleZenMD primarily dispenses compounded versions, which are not the studied products and are not FDA-reviewed for safety or efficacy; the expectation is that the same active molecule behaves similarly, but that's an inference, not trial data. And microdosing — a core part of TeleZenMD's pitch — runs below the doses these trials used. The company is candid that microdosing trades peak speed for tolerability and adherence; that's a reasonable clinical rationale, but there isn't a large trial base showing microdose protocols match full-dose weight loss. Results vary with starting weight, dose, consistency, and the behavioral side.

GLP-1 therapy is well-characterized, and the side-effect profile is consistent across the class. The most common effects are gastrointestinal: nausea, reduced appetite, constipation or diarrhea, and mild digestive discomfort, usually most noticeable when starting or stepping up a dose and often easing with time and dose adjustment — which is part of the argument for the microdose on-ramp. Less common but more serious risks documented for the class include pancreatitis and gallbladder problems. Branded GLP-1s also carry a boxed warning based on rodent studies of thyroid C-cell tumors, and are not recommended for people with a personal or family history of medullary thyroid carcinoma or MEN2; pregnancy is another contraindication. TeleZenMD's pages list the common, mild effects but don't foreground these contraindications — a prescribing provider is supposed to screen for them at intake, and patients should raise them directly.

Eligibility is described as a BMI of 27 or higher with at least one weight-related condition, or other clinical indications, with final approval at the provider's discretion. This is the standard threshold and a reasonable gate; it also means not everyone who applies will be approved, which is appropriate.

None of this is unique to TeleZenMD — it's the GLP-1 category's standard risk picture — but a thorough review should state it, and a good provider relationship should surface it before you pay.

The single most important context for any compounded-GLP-1 provider in 2026 is the regulatory squeeze. The FDA removed tirzepatide from its shortage list in December 2024 and semaglutide in February 2025; the 503A grace period ended 22 April 2025 and the 503B grace period 22 May 2025. On 30 April 2026 the agency proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List permanently, with public comment open until 29 June 2026. The practical effect is that mass-compounding of these drugs no longer rests on a shortage justification; what remains is narrower, patient-specific compounding. Compounded medications are not FDA-approved and don't undergo the same safety, effectiveness, or manufacturing review as branded drugs — TeleZenMD discloses this clearly on its pages.

One thing we'd ask the company to clean up: its pharmacy description contradicts itself — sometimes on a single page. On the main GLP-1 therapy page, the benefits panel lists "U.S. 503A Compounding Pharmacies" and one FAQ states the company works "only with U.S.-licensed 503A compounding pharmacies," while two other FAQs on that same page say medications are sourced from "U.S.-based, state-licensed 503A and 503B compounding pharmacies." The sermorelin, NAD+, and PT-141 pages, meanwhile, say TeleZenMD works "exclusively with US-licensed, quality-audited 503A compounding pharmacies." 503A (patient-specific) and 503B (bulk outsourcing) are meaningfully different regulatory categories, so "exclusively 503A" and "503A and 503B" can't both be precisely true. It's likely sloppy copy rather than anything sinister, but for a company selling on trust and transparency, having both claims live on one page is exactly the kind of detail a buyer — and a reviewer — notices. We'd want it clarified before treating either claim as settled.

Because availability of compounded tirzepatide specifically is the most regulation-sensitive data point here, we'll recheck it after the 29 June 2026 comment deadline.

Breadth is TeleZenMD's real differentiator, so it's worth making concrete rather than hand-waving "they do a lot." Pricing across the non-GLP-1 programs is notably uniform — most injectables land at the same $148 first month / $198 thereafter, $498 quarterly ladder as standard GLP-1 — which suggests a pricing template more than per-therapy economics. Highlights from the menu, with prices pulled across the NAD+, sermorelin, and PT-141 product pages on 10 June 2026:

For PeptideWellness's purposes, this is the useful part: TeleZenMD is relevant to the GLP-1, recovery, longevity, sexual-health, hormone, and skin/hair clusters at once. The flip side of selling everything is that the depth varies — bremelanotide has a genuine FDA-approved pedigree (Vyleesi, NDA 210557), while "methylene blue for brain health" is marketed well ahead of its evidence: there is no FDA approval for any cognitive use, and the peer-reviewed RCT base for Alzheimer's shows only preliminary, mixed-to-modest results. A buyer should treat the menu as a convenience, not as equal clinical footing across items.

We'll also note, since we read the pages closely: the marketing polish is uneven. The NAD+ page carries a garbled testimonial byline ("LindseLisa R., 39y S., 50") and includes an acne testimonial ("I thought I was stuck with adult acne forever, but this prescription formula cleared my skin within weeks") under an energy therapy page — both still present on the live page as of 10 June 2026. Co-founder Lina Viner's title also shifts page to page — "Co-Founder & Head of Education" and "Creator of Lose It For Life" on the GLP-1 page, but "Head of Education & Behavioral Science" on the microdose and NAD+ pages — and the same "weight set point / subconscious patterns" founder quote is reused verbatim across both weight-loss pages. None of this is disqualifying, but it reads as fast-growing-startup copy, not the buttoned-up operation the premium framing implies.

Every GLP-1 plan includes Lose it for Life, the company's flagship behavioral program, created by co-founder Lina Viner and built around what TeleZenMD calls "The Rewire Method." It's a set of roughly 10 structured modules aimed at the parts medication doesn't touch: emotional eating, self-sabotage, stress-driven cravings, and nervous-system regulation. The thesis the company leans on hard — repeated across the site — is that "most people who lose weight with GLP-1 medication gain it back within a year" unless the underlying patterns change.

Here's the honest read. The underlying idea is mainstream and defensible: behavior change and relapse prevention genuinely matter for durable weight loss, and weight regain after stopping GLP-1s is a real, documented phenomenon — the STEP 1 extension trial documented that participants regained roughly two-thirds of the weight they had lost within a year of stopping semaglutide. Pairing medication with structured support is a reasonable model, and including it at no extra charge is a real differentiator — the pure-medication funnels don't offer anything comparable. The cautions are equally real: the "most people regain within a year" line is presented as marketing framing rather than tied to a specific citation; the program's "$998 value" is a marketing figure, not an audited price; and the "neuroscience-based" and "subconscious retraining" language describes a proprietary method, not a peer-reviewed protocol. We'd treat the program as a credible value-add to the medical care, not as clinically proven on its own terms.

Pros.

Widest menu in our set. If you may want more than weight loss — recovery, longevity, sexual health, hormones, skin and hair — it's all under one roof with one care team.

Public, upfront pricing. Real numbers before any signup, with FSA/HSA eligibility and buy-now-pay-later options.

Verified prescriber base — four prescribers listed across product pages (two MDs and two DOs), all four cross-checked against the public NPI Registry as holding current state licenses. Taxonomy mix includes Preventive/Obesity Medicine, Family Medicine, and Internal Medicine — consistent with the "obesity medicine" framing the company uses on its pages.

Behavioral program included at no extra cost — a genuine structural difference from the medication-only competitors.

Microdose pathway for patients who want a lower-dose, lower-side-effect approach or are maintaining rather than chasing fast loss.

Clear regulatory disclosure that compounded medications aren't FDA-approved.

Cons and trade-offs.

The best rates require paying in full upfront — up to $1,598 (semaglutide) or $2,598 (tirzepatide) at checkout for the annual plans.

Inconsistent details — the pharmacy description (503A vs 503A/503B) and the promo-code stack don't line up across the site.

Headline trust stats are self-reported — and third-party data is sparse. TeleZenMD's pages claim "100,000+ patients," "4.9 Google rating," "99% five-star reviews," and "97% would recommend." External signals are thinner: Trustpilot shows 4 stars across just 15 reviews, no accredited BBB profile turned up in search, and we found no meaningful TeleZenMD-specific Reddit discussion. Treat the company figures as marketing claims, not verified statistics.

Uneven marketing polish — recycled or garbled testimonials and a menu item (methylene blue) marketed ahead of its evidence.

Guarantee and refund terms — the "180-day guarantee" is conditional on following the program; the full refund mechanics live on a separate Returns & Refunds page.

Compounded medications are not FDA-approved, and tirzepatide availability is regulation-sensitive (recheck after the FDA's 29 June 2026 comment deadline).

TeleZenMD makes the most sense for the patient who wants a system, not just a syringe: someone who suspects the behavioral side is their real obstacle and values coaching, education, and a call-or-text support team bundled in. It also fits people who expect their needs to extend past GLP-1 — into hormones, longevity, sexual health, or skin and hair — and would rather keep everything with one provider. And it suits patients who can comfortably prepay for a quarter or more to capture the lower monthly-equivalent rates, and who want to use FSA/HSA dollars.

Skip it if your single priority is the lowest possible sticker price — the budget tier starts lower on paper, and TeleZenMD's best rates are locked behind upfront multi-month payment. Skip it if you can't or won't prepay a quarter-plus, since the month-to-month rate ($198 standard semaglutide) is mid-pack rather than cheap. Skip it if you want to run treatment through insurance — this is cash-pay only, and an insurance-forward provider will serve you better. And approach with extra diligence if a long, independently verified track record matters to you, until the self-reported numbers and the small inconsistencies are cleared up.

We keep dose-by-dose, head-to-head verdicts in our comparison pages rather than here, but the shape of it is straightforward. Against the budget GLP-1 funnels, TeleZenMD costs more month-to-month but bundles a behavioral program and a far wider menu. Against the premium DTC names, it competes less on brand polish — which, as noted, is uneven — and more on breadth and the included coaching. Against an insurance-forward option, it's a different model entirely: cash-pay simplicity versus the chance of a lower out-of-pocket cost if your plan cooperates. The clearest reason to choose TeleZenMD over any of them is that you want one provider for several goals, plus the behavioral layer, and you're paying cash anyway.

How we reviewed this. Pricing, programs, and process details were pulled directly from TeleZenMD's public pages (home, GLP-1 therapy, microdose, sermorelin, NAD+, PT-141, and FAQ) in June 2026, cross-checked against the published GLP-1 trials the company cites (NEJM STEP and SURMOUNT) and FDA compounding guidance. Prescriber roster was verified independently against the public NPI Registry (CMS) in June 2026 — all four prescribers listed on TeleZenMD's product pages are individually registered with current state licenses. Third-party review platforms: Trustpilot shows a 4-star rating across only 15 reviews — a small sample, but external; we found no accredited BBB profile and no meaningful TeleZenMD-specific Reddit discussion at the time of writing. We do not publish invented customer experiences; the testimonials and statistics on TeleZenMD's own site are the company's, not ours, and are labeled as such.

Editorial independence. PeptideWellness does not accept payment from telehealth providers, compounding pharmacies, or manufacturers in exchange for coverage, placement, or scoring. We have no commercial relationship with TeleZenMD.

Editorial note: Informational only — not medical advice. Compounded medications aren't FDA-approved and don't undergo the same safety, effectiveness, or manufacturing review as branded pharmaceuticals. GLP-1 and peptide therapy decisions should be made with a licensed healthcare provider familiar with your medical history. Last reviewed June 2026.